Program
resiquimod
Also written as “BDB-001 injection”, “EIK1001” and “BDB-001 Injection”.
Its studies are mostly in Neoplasms · Neoplasm Metastasis · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · COVID-19 · Hidradenitis Suppurativa, led by 2 companies.
Drug pageBDB001: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Staidson (Beijing) Biopharmaceuticals | 81 open or running | phase 3since Jun 26, 2020 | Jun 26, 2020 | Apr 16, 2027phase 3 · NCT07168161 |
| Eikon Therapeuticsits history only | 63 open or running | phase 3since Nov 18, 2024 | Feb 28, 2018 | Dec 2026phase 2 · NCT06246110 |
Also a collaborator on its studies: Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Staidson (Beijing) Biopharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2019Named resiquimodINNProposed as its International Nonproprietary Name in WHO's List 122 · before, EIK1001, BDB001
- Jun 26, 2020First study: phase 3 study in COVID-19First studyNCT04449588 · 369 enrolled · Bangladesh, China, India and more
- Jun 23, 20212 phase 2 studies in Hidradenitis SuppurativaNCT05103423, NCT05093855
- Aug 22, 2021Phase 1 study in COVID-19NCT05075304 · 18 enrolled · China
- Dec 2, 2021Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT05197842 · 93 enrolled · China
- Apr 29, 20222 phase 1 studies in HealthyNCT05361005, NCT05360927
- Sep 4, 2025Phase 3 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07168161 · 300 planned · China
Ahead
- Apr 16, 2027Primary completion: phase 3 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07168161
TargetBeta
“The sulfate salt form of resiquimod, a toll-like receptor type 7 and 8 (TLR7/8) agonist, ”NCIt, by rule
“Toll-like receptor 8 agonist; Toll-like receptor 7 agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enpatoranrule | Merck KGaA, Darmstadt, Germany | phase 3 | 12 |
| afimetoranrule | Bristol-Myers Squibb | phase 3 | 12 |
Studies
All 8 Staidson (Beijing) Biopharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07168161Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · China | 3 | Recruiting | Apr 16, 2027 | 300 |
| NCT05361005Healthy · China | 1 | Completed | May 8, 2020 | 33 |
| NCT05360927Healthy · China | 1 | Completed | Dec 25, 2020 | 28 |
| NCT05197842Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · China | 2 | Completed | Mar 19, 2025 | 93 |
| NCT05075304COVID-19 · China | 1 | Terminated | Apr 14, 2020 | 18 |
| NCT05103423Hidradenitis Suppurativa · China | 2 | Completed | Jul 7, 2023 | 50 |
| NCT05093855Hidradenitis Suppurativa · China | 2 | Completed | Aug 22, 2023 | 41 |
| NCT04449588COVID-19 · Bangladesh, China, India and more | 3 | Terminated | Mar 26, 2024 | 369 |
How it is read
Names in the registry
- “BDB-001 injection”, 7 entries
- “EIK1001”, 3 entries
- “BDB-001 Injection”, 3 entries
- “BDB001 (EIK1001)”, 2 entries
- “BDB001”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 3 studies
- Neoplasm Metastasis, 2 studies
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, 2 studies
- COVID-19, 2 studies
- Hidradenitis Suppurativa, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.